

## CURRICULUM VITAE

### Traci Heath Mondoro

**Work Address:**

6705 Rockledge Drive  
Room 408-C, MSC 7950  
Bethesda, MD 20892  
(301) 827-8283  
mondorot@nhlbi.nih.gov

**Academic Degrees:**

BS

1989 College of William and Mary  
Williamsburg, Virginia (Biology)  
(Chemistry minor)

Ph.D.

1994 University of Tennessee  
Memphis, Tennessee (Biochemistry)

**Appointments:**

2022-present

Acting Chief, Blood Epidemiology and Clinical Therapeutics  
Branch, Division of Blood Diseases and Resources (DBDR),  
NHLBI

2018-present

Program Director, NHLBI Cure Sickle Cell Initiative

2014-present

Chief, Translational Blood Science and Resource Branch,  
DBDR, NHLBI

2008-2014

Deputy Chief, Transfusion Medicine and Cellular  
Therapeutics Branch/DBDR, NHLBI

2007-2008

Acting Chief, Thrombosis and Hemostasis  
Branch/DBDR/NHLBI

2001-2007

Health Scientist Administrator, Transfusion Medicine and  
Cellular Therapeutics Branch/NHLBI

2000-2001

Staff Scientist, Laboratory of Cellular Hematology/Center  
for Biologics Evaluation and Research (CBER)/FDA

1996-2000

FDA Staff Fellow, Laboratory of Cellular  
Hematology/CBER/FDA

1994-1996

National Research Council Fellow/Laboratory of Cellular  
Hematology/CBER/FDA

1989-1994

Teaching Assistant/Graduate Student, Department of  
Biochemistry, University of Tennessee, Memphis

## Awards and Honors

- 2022 NIH Director's Award as member of the Accelerating COVID-19 Therapeutic Interventions and Vaccines Team
- 2018 NIH Director's Award in recognition of building the Cure Sickle Cell Initiative
- 2018 AABB President's Award in recognition of dedication to public service and leadership
- 2015 NHLBI Partnership/Collaboration Award for dedication, cooperation, and perseverance in supporting NHLBI's role in early translational research
- 2014 NIH Director's Award for exceptional leadership in establishing the NIH Centers for Accelerated Innovations Program
- 2014 NICHD Partnership Award for partnering in the Transfusion of Prematures Study
- 2010 NIH Merit Award in recognition of exceptional teamwork and leadership in developing and managing research programs in cell therapy and transfusion medicine
- 2009 NINDS Collaboration Award in recognition of representing NHLBI on the NIH Rapid Acceleration of Innovative Discoveries (RAID) program
- 2006 NIH Merit Award in recognition of exceptional teamwork and leadership in building the NHLBI PACT program to facilitate clinical utility of cellular therapies
- FDA Commendable Service Award, 2000
- FDA Reward and Recognition Awards 1997-2000
- National Research Council Fellow, 1994-1996
- Ralph R. Braund Young Investigator Award for Cancer Research, 1994
- American Society of Hematology Travel Awards, 1991-1993

## Publications

1. Benz EJ Jr., **Mondoro TH**, Gibbons GH. Accelerating the Science of SCD Therapies—Is a Cure Possible? *JAMA* 322: 921-922, 2019.
2. Ebert RF, Danthi NS, Charette MF, Hanspal M, **Mondoro TH**, Noel PJ, Olive M, Punturieri A, Moore, TM. The NHLBI SMARTT Program: A Novel Approach to Facilitate Translational Research for Heart, Lung, and Blood Diseases. *Circ Res.* 118: 1867-1871, 2016.
3. Josephson CD, **Mondoro TH**, Ambruso DR, Sanchez R, Sloan SR, Luban NLC, Widness JA. One Size Will Never Fit All: Clinical and Translational Research Gaps in Pediatric Transfusion Medicine. *Pediatr Res.* 76: 425-431, 2014
4. Wood D, Wesselschmidt R, Hematti P, Gee AP, Rooney C, Silberstein L, Armant M, Couture L, Wagner JE, McKenna DH, Hei D, **Mondoro TH**, Welniak L, Lindblad R. An Update from the United States National Heart, Lung, and Blood institute-funded Production Assistance for Cellular Therapies (PACT) Program: A Decade of Cell Therapy. *Clin Transl Sci.* 7: 93-99, 2014.

5. Sanchez R, Silberstein LE, Lindblad RW, Welniak L, **Mondoro TH**, Wagner JE. Strategies for More Rapid Translation of Cellular Therapies for Children: A US Perspective. *Pediatrics*. 132: 351-358, 2013.
6. **Mondoro TH**. Data Safety Monitoring Boards: A word from a sponsor (NHLBI). *Transfusion*. 49: 1537-1539, 2009.
7. Reed W, Noga S, Gee AP, Rooney C, McKenna D, Wagner J, Donnenberg A, Whiteside TL, Baker A, Lindblad R, Wagner E, **Mondoro TH**. Production Assistance for Cellular Therapies (PACT): Four-Year Experience From The United States National Heart Lung And Blood Institute (NHLBI) Contract Research Program in Cell and Tissue Therapies. *Transfusion*. 49:786-796, 2009.
8. Hillyer CD, **Mondoro TH**, Josephson CD, Sanchez R, Sloan SR, Ambruso DR. Pediatric transfusion medicine: development of a critical mass. *Transfusion*. 49:596-601, 2009
9. **Mondoro TH**, Thomas JW, Henslee-Downey PJ, Peterson CM. NHLBI plans for the promise of cell-based therapies. *Cytotherapy*. 2005; 7:317-27.
10. **Mondoro TH**, Vostal JG. Cold temperatures reduce the sensitivity of stored platelets to disaggregating agents. *Platelets*. 2002; 13:11-20.
11. Eggerman TL, **Mondoro TH** , Lozier JN , and Vostal JG Adenoviral vectors do not induce, inhibit or potentiate human platelet aggregation, *Hum Gene Ther*. 2002 13: 125-138.
12. Lozier JN, Csako G, **Mondoro TH**, Krizek DM, Metzger ME, Costello R, Vostal JG, Rick ME, Donahue RE, Morgan RA. Toxicity of a first-generation adenoviral vector in rhesus macaques. *Hum Gene Ther*. 2002 13:113-124
13. **Mondoro TH**, Brockner Ryan, BA, Hrinzenko BW, Schechter AN, Vostal JG, Alayash AI: Biological action of nitric oxide donor compounds on platelets from patients with sickle cell disease. *Br J Haem*, 112:1048-1054, 2001.
14. **Mondoro TH**, White MM, and Jennings LK: Active GPIIb-IIIa conformations that link ligand interaction with cytoskeletal reorganization. *Blood*, 96:2487-2495, 2000.
15. Vostal JG, Reid TJ, **Mondoro TH**: Summary of a workshop on *in vivo* efficacy of transfused platelets and platelet products. *Transfusion*, 40:742-750, 2000.
16. Vostal JG and **Mondoro TH**: Cold Stored Platelets in Platelet Therapy: in Platelet Therapy--Current Status and Future Challenges, Eds J. Seghatchian and E. Snyder, Elsevier Science, Amsterdam, 1999.
17. **Mondoro TH**, Shafer BC, Vostal JG: Restoration of responses in room temperature stored platelets resuspended in plasma stored frozen or at room temperature. *Am J Clin Path*, 111:693-699, 1999.
18. Holada K, **Mondoro TH**, Vostal JG: Increased expression of phosphatidylinositol-specific phospholipase C resistant prion proteins on the surface of activated platelets. *Br J Haem*, 103:273-280, 1998.
19. **Mondoro TH**, Alayash AI, Brockner Ryan BA, Terle DA, and Vostal JG: Hemoglobin A<sub>0</sub> and  $\alpha$ -crosslinked hemoglobin (DBBF- $\alpha$ ) potentiate agonist-induced platelet aggregation through the platelet thromboxane receptor. *Art Cells, Blood Subs, and Immob Biotech*, 26:1-16,1998.
20. Vostal JG and **Mondoro TH**: Liquid cold storage of platelets: a revitalized possible alternative for limiting bacterial contamination of platelet products. *Transfus Med Rev* 11:286-295, 1997.

21. **Mondoro TH**, Shafer BC, and Vostal JG: Peroxynitrite-induced tyrosine nitration and phosphorylation in human platelets. *Free Radical Biol. Med.* 22:1055-1063, 1997.
22. **Mondoro TH**, Wall CD, White MM, and Jennings LK: Selective induction of a GPIIIa LIBS by fibrinogen and von Willebrand factor. *Blood* 88:3824-3830, 1996
23. Vostal JG, Shafer BC, **Mondoro TH**, and Fratantoni JC: Endogenous ADP prevents PGE<sub>1</sub>-induced tyrosine dephosphorylation of focal adhesion kinase in thrombin activated platelets. *Biochem. Biophys. Acta* 1314:1-12, 1996.
24. Jennings LK, Slack SM, Wall CD, and **Mondoro, TH**: Immunological comparisons of integrin  $\alpha_{IIb}\beta_3$  (GPIIb-IIIa) expressed on platelets and human erythroleukemia cells: evidence for cell specific differences. *Blood Cells, Molecules, and Diseases* 22:23-35, 1996
25. **Heath TL**, Wall CD, and Jennings LK: A GPIIIa LIBS antibody detects multiple GPIIb-IIIa conformations and its binding is modulated by various ligands. *Ann. NY Acad. Sci.* 714, 300-303, 1993.

**Publications from Clinical Trials when serving as Program Officer or Executive Secretary of NHLBI Data Safety Monitoring Board**

1. Connors JM, Brooks MM, Sciruba FC, *et al.* Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. *JAMA*. 2021 Nov 2;326(17):1703-1712.
2. Hochman JS, Zarychanski R *et al.* Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. *N Engl J Med*. 2021 Aug 26;385(9):790-802.
3. Hochman JS, Webb SA, Zarychanski R, *et al.* Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. *N Engl J Med*. 2021 Aug 26;385(9):777-789.
4. Kirpalani H, Bell EF, Hintz SR, *et al.* Higher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants. *N Engl J Med*. 2020 Dec 31;383(27):2639-2651.
5. Spinella PC, Tucci M, Fergusson DA, *et al.* Effect of Fresh vs Standard-issue Red Blood Cell Transfusions on Multiple Organ Dysfunction Syndrome in Critically Ill Pediatric Patients: A Randomized Clinical Trial. *JAMA*. 2019 Dec 10;322(22):2179-2190.
6. Price TH, Boeckh M, Harrison RW, *et al.* Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. *Blood*. 2015 Oct 29;126(18):2153-61.
7. Steiner ME, Ness PM, Assmann SF, *et al.* Effects of red-cell storage duration on patients undergoing cardiac surgery. *N Engl J Med*. 2015 Apr 9;372(15):1419-29.
8. Leissinger C, Josephson CD, Granger S, *et al.* Rituximab for treatment of inhibitors in haemophilia A. A Phase II study. *Thromb Haemost*. 2014 Sep 2;112(3):445-58.
9. Carson JL, Terrin ML, Noveck H, *et al.* Liberal or restrictive transfusion in high-risk patients after hip surgery. *N Engl J Med*. 2011 Dec 29;365(26):2453-62.
10. Slichter SJ, Kaufman RM, Assmann SF, *et al.* Dose of prophylactic platelet transfusions and prevention of hemorrhage. *N Engl J Med*. 2010 Feb 18;362(7):600-13.